<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A 32-year old female with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> presented 8 months after mitral valve reconstruction with progressive <z:hpo ids='HP_0002875'>exertional dyspnea</z:hpo> and echocardiographically demonstrable critical <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo> and regurgitation </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001649'>Tachycardia</z:hpo>, <z:hpo ids='HP_0001824'>weight loss</z:hpo>, <z:hpo ids='HP_0002360'>sleep disturbances</z:hpo> and increasing nervosity led to the diagnosis of concomitant <z:hpo ids='HP_0000836'>hyperthyroidism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>After the patient stopped the oral anticoagulation by herself, a 'catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>' with multiple microthromboembolic events in several organs developed rapidly within a few weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Severe <z:hpo ids='HP_0002093'>respiratory failure</z:hpo> was observed 14 days after admission at our hospital because of a <z:hpo ids='HP_0100598'>pulmonary edema</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>TREATMENT: Removal of the annuloplasty ring and alloplastic mitral valve replacement with a 25 mm bilifleat valve </plain></SENT>
<SENT sid="5" pm="."><plain>Postoperatively, the patient was placed on oral anticoagulation </plain></SENT>
<SENT sid="6" pm="."><plain>Several pre- and postoperative plasmaphereses lowered the level of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The patient additionally underwent radioiodtherapy 5 months postoperatively </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: While hemodynamics and <z:mp ids='MP_0001762'>diuresis</z:mp> remained sufficient, ventilatory support with tracheostomy was necessary for 16 postoperative days to achieve stable respiration </plain></SENT>
<SENT sid="9" pm="."><plain>Thirty months later, the patient is well and without further cardiac and neurological dysfunction </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Secondary cardiac valve operations on patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> may be successfully performed within a multidisciplinary approach </plain></SENT>
<SENT sid="11" pm="."><plain>Oral anticoagulation remains the treatment of choice to prevent further <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
</text></document>